University of Washington researchers introduced engineered protein switches that regulate therapeutic protein activity by controlling binding duration rather than affinity. This innovative approach, detailed in Nature, offers unprecedented real-time control over drug function, potentially improving safety and efficacy profiles of protein-based medicines. Such molecular precision could revolutionize treatment regimes by minimizing off-target effects and customizing therapies.